Paul Edick

Paul Edick

Former Chief Executive OfficeratXeris Biopharma Holdings· In proxies 2021–2024

Pay in FY2022-25% from the year before · Xeris Biopharma Holdings stock -54.6% the same year

Paul Edick was paid $2.8M in FY2022 (Dec), down 25%. Xeris Biopharma Holdings stock fell 54.6% that year.

Pay$100 in the stock at the end of FY20 → $27
Pay is from the Summary Compensation Table of each Xeris Biopharma Holdings proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Xeris Biopharma HoldingsPublic company · 5 yr
    • Former Chief Executive Officer2021 – Present · 5 yrStock in role +95%
  2. Milestone Pharmaceuticals Inc.Public company · 1 yr
    • Director2019 – 2020 · 1 yrNo stock prices for these years
  3. Iterum Therapeutics LimitedPublic company · 4 yr
    • Director2015 – 2019 · 4 yrNo stock prices for these years
  4. Sucampo Pharmaceuticals, Inc.Public company · 2 yr
    • Director2016 – 2018 · 2 yrNo stock prices for these years
  5. Neos Therapeutics, Inc.Public company · 3 yr
    • Director2015 – 2018 · 3 yrNo stock prices for these years
  6. PDL BioPharma, Inc.Public company · 3 yr
    • Director2015 – 2018 · 3 yrNo stock prices for these years
  7. NewLink Genetics Corp.Public company · 7 yr
    • Director2011 – 2018 · 7 yrNo stock prices for these years
  8. Circassia Pharmaceuticals PlcPublic company · 3 yr
    • Director2013 – 2016 · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?